Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Core Insights - Adial Pharmaceuticals has received a new patent (number 12,221,654) for methods related to identifying patients with specific genetic markers linked to substance use disorders and treating them with its investigational drug AD04 [1][2] - The treatment approach focuses on detecting the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4) and is aimed at individuals suffering from disorders such as opioid dependence and alcohol dependence [2][3] - The CEO of Adial Pharmaceuticals emphasized the significance of this patent as a milestone in developing personalized treatments for addiction, highlighting the potential of AD04 to treat various drug dependencies beyond alcohol use disorder [3][4] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders, with its lead investigational drug AD04 being a genetically targeted serotonin-3 receptor antagonist [4] - AD04 has shown promising results in the ONWARD™ pivotal Phase 3 clinical trial, which focused on reducing heavy drinking in patients with specific target genotypes, and no significant safety or tolerability issues were reported [4] - The company believes AD04 may also be effective in treating other addictive disorders, including opioid use disorder, gambling, and obesity [4]